AKT1 and melanoma: Additionally, in our B16 mouse model of melanoma dormancy [5], we showed that persistent tumor cells that escaped cancer vaccine therapy displayed SC-like properties and that the balance between their quiescence and proliferation was controlled by FOXO3a, a downstream target of AKT.